Valuation: PTC Therapeutics, Inc.

Market Cap 6.12B 5.29B 4.94B 4.53B 8.53B 582B 8.66B 57.99B 22.76B 292B 22.98B 22.47B 965B P/E 2026 *
42.2x
P/E 2027 * 26.4x
Enterprise Value 6.09B 5.27B 4.92B 4.51B 8.49B 580B 8.62B 57.71B 22.65B 290B 22.87B 22.37B 960B EV / Sales 2026 *
4.82x
EV / Sales 2027 * 2.92x
Free-Float
92.6%
Yield 2026 *
-
Yield 2027 * -
1 day+3.47%
1 week+7.79%
Current month+7.79%
1 month-17.81%
3 months+13.68%
6 months-1.83%
Current year-3.49%
1 week 66.07
Extreme 66.07
73.37
1 month 64.57
Extreme 64.5675
90.87
Current year 61.43
Extreme 61.43
90.87
1 year 43.18
Extreme 43.175
90.87
3 years 17.53
Extreme 17.53
90.87
5 years 17.53
Extreme 17.53
90.87
10 years 4.03
Extreme 4.03
90.87
Manager TitleAgeSince
Chief Executive Officer 54 22/03/2023
Director of Finance/CFO 41 13/07/2023
Chief Tech/Sci/R&D Officer - 01/10/2017
Director TitleAgeSince
Chairman 74 01/11/2004
Chairman 80 31/03/1998
Director/Board Member 65 01/12/2005
Date Insider Type Main position Quantity % Market Cap.
4/8/26 Sell

Chief Executive Officer

-10,292 0.0124%
28/7/26 Other

Director

200,401 0.2416%
28/7/26 Free

Director

11,213 0.0135%
Change 5-day change 1-year change 3-year change Capi.($)
+3.47%+7.79%+45.57%+93.07% 6.12B
-0.52%+3.21%+85.02%+161.12% 1,057B
+0.88%+1.13%+51.13%+49.76% 625B
+0.89%-1.95%+23.73%+63.67% 435B
+0.71%+3.87%+47.45%+38.68% 363B
+0.64%-0.49%+35.39%+40.21% 296B
+0.39%-5.83%+8.64%+9.28% 249B
+1.51%+6.69%+44.34%+62.47% 222B
+3.92%-0.46%-1.21%-44.09% 209B
+1.80%+2.30%+20.79%+65.13% 165B
Average +1.53%+1.56%+36.09%+53.93% 362.69B
Weighted average by Cap. +1.13%+1.23%+48.33%+75.36%

Financials

2026 *2027 *
Net sales 1.26B 1.09B 1.02B 936M 1.76B 120B 1.79B 11.97B 4.7B 60.27B 4.74B 4.64B 199B 1.36B 1.18B 1.1B 1.01B 1.9B 130B 1.93B 12.91B 5.07B 64.96B 5.11B 5B 215B
Net income 153M 133M 124M 114M 214M 14.59B 217M 1.45B 570M 7.31B 576M 563M 24.17B 214M 185M 173M 159M 299M 20.39B 303M 2.03B 797M 10.22B 804M 787M 33.78B
Net Debt -29.41M -25.44M -23.75M -21.79M -40.98M -2.8B -41.64M -279M -109M -1.4B -110M -108M -4.64B -2.15B -1.86B -1.73B -1.59B -2.99B -204B -3.04B -20.33B -7.98B -102B -8.06B -7.88B -338B
Logo PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).
Employees
991
Date Price Change Volume
07/08/26 USD 73.31 +3.47% 963,179
06/08/26 USD 70.85 +2.37% 928,898
05/08/26 USD 69.21 +0.16% 1,102,512
04/08/26 USD 69.10 +1.45% 1,420,925
03/08/26 USD 68.12 +0.15% 1,367,720
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
73.31USD
Average target price
97.86USD
Spread / Average Target
+33.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTCT Stock